Kidney Function Indicators Predict Adverse Outcomes of COVID-19

Abstract

Background The coronavirus disease 2019 (COVID-19) is an emerged respiratory infectious disease with kidney injury as a part of the clinical complications. However, the dynamic change of kidney function and its association with COVID-19 prognosis are largely unknown. Methods In this multicenter retrospective cohort study, we analyzed clinical characteristics, medical history, laboratory tests, and treatment data of 12,413 COVID-19 patients. The patient cohort was stratified according to the severity of the outcome into three groups: non-severe, severe, and death. Findings. The prevalence of elevated blood urea nitrogen (BUN), elevated serum creatinine (Scr), and decreased blood uric acid (BUA) at admission was 6.29%, 5.22%, 11.66%, respectively. The trajectories showed elevation of BUN level and Scr level, as well as a reduction of BUA level during 28 days after admission in death cases. Increased all-cause mortality risk was associated with elevated baseline levels of BUN and Scr, and decreased level of BUA. Conclusion The dynamic changes of the three kidney function markers were associated with different severity and poor prognosis of COVID-19 patients. BUN showed close association and high potential for predicting adverse outcomes in COVID-19 patients for severity stratification and triage.

Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients

“…A part of the baseline data in this manuscript have been used in our previous articles. 30 , 31 , 32 , 33 …”

Permanent atrial fibrillation portends poor outcomes in hospitalized patients with COVID-19: A retrospective observational study

“…Our results revealed that abnormal CT findings were more prominent in patients with AF. Recently studies have shown that elevated troponin, D-dimer, urea, CRP concentrations, lower albumin levels and lower lymphocyte counts were associated with severe complications of COVID-19 [ [31] , [32] , [33] ]. The results of our study have confirmed previous findings on these biochemical markers.…”

COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options

“…The study was limited by its low sample size of 86 patients, but found no benefit of LPV/r in the rate of positive-to-negative conversion of SARS-CoV-2 nucleic acid or improvement in symptoms or imaging. In fact, the therapy only increased adverse events from primarily diarrhea and loss of appetite in the LPV/r arm [ 42 ].…”

“…Favipiravir and umifenovir are broad antivirals approved in countries outside the USA that were used as anti-influenza agents. Both drugs have had limited clinical data supporting their use, although there has been some in vitro data [ 40 , 42 , 95 , 96 ]. Sofosbuvir/daclatasvir is a treatment for hepatitis C infection that has also been found to bind to SARS-CoV-2 [ 97 ].…”